Review



csf2rb  (Santa Cruz Biotechnology)


Bioz Verified Symbol Santa Cruz Biotechnology is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Santa Cruz Biotechnology csf2rb
    (A) Proportion of mutation types across recurrently mutated genes. (B) Lollipop diagram depicting the distribution of <t>CSF2RB</t> mutations in our in-house cohort. (C) WB analysis of CSF2RB expression and phosphorylation status of STAT5 in the L-428 model. Representative images are shown (left). Densitometry analysis was carried out by Image Lab (right). Data are presented as mean ± SEM. Statistical analyses were conducted using one-way ANOVA followed by Dunnett’s multiple comparisons test. (D) Top pathways from LymphoChip upregulated in E788* cells compared to WT cells in the L-428 model. (E) Heatmap showing transcript levels of genes in the L-428 model. Genes with consistent expression changes (absolute fold change ≥ 1.4) across all three experimental models (L-428, U-HO1 + IL-3, U-HO1 + IL-5) are shown. (F) TARC and IL-13 concentrations in supernatant of L-428 model at baseline. Data are presented as mean ± SEM. Statistical analyses were conducted using one-way ANOVA followed by Dunnett’s multiple comparisons test (TARC), and a negative binomial regression model to account for overdispersion in the data (IL-13). (G) TARC and IL-13 concentrations in supernatant of L-428 (left) model treated with pacritinib (0.5 μM) for 48 hours, and U-HO1 (right) model in the presence of IL-3 (1 ng/mL) or IL-5 (1 ng/mL) treated with or without pacritinib (0.5 μM) for 48 hours. Data are presented as mean ± SEM. Pre- and post-treatment comparisons were conducted using an unpaired, two-sided t -test for each cell type. (H) CCR4+CD4+ T cell migration towards L-428 CSF2RB WT or E788* supernatant in a transwell migration assay, showing the percentage of migrated cells relative to the input control. A paired, two-sided t -test was used to compare the two conditions. Data are presented as mean ± SEM (n=4). (I) Spleen tissues from humanized mouse model, sacrificed at 12 weeks after CB injection, were stained with hematoxylin and eosin (H&E), CD30, CD4, PAX5, and FOXP3. The image is presented at a magnification of 20X. (J) Percentage of CD4+CD25+FOXP3+ Tregs identified in spleen of humanized CNW mice engrafted with L-428 CSF2RB WT or E788* cells by FCM. An unpaired, two-sided t -test was used to compare the two conditions, and data are shown as the mean ± SEM (n=6 for WT and n=5 for E788*). (K) Bar graph depicts serum TARC concentration from CNW mice engrafted L-428 WT (n=6) and E788* (n=5) cells, sacrificed at 12 weeks after CB injection. An unpaired, two-sided t -test was used to compare the two conditions. The data are shown as mean ± SEM.
    Csf2rb, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 19 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/csf2rb/product/Santa Cruz Biotechnology
    Average 93 stars, based on 19 article reviews
    csf2rb - by Bioz Stars, 2026-03
    93/100 stars

    Images

    1) Product Images from "Multidimensional characterization of cellular ecosystems in Hodgkin lymphoma"

    Article Title: Multidimensional characterization of cellular ecosystems in Hodgkin lymphoma

    Journal: bioRxiv

    doi: 10.1101/2025.03.18.643177

    (A) Proportion of mutation types across recurrently mutated genes. (B) Lollipop diagram depicting the distribution of CSF2RB mutations in our in-house cohort. (C) WB analysis of CSF2RB expression and phosphorylation status of STAT5 in the L-428 model. Representative images are shown (left). Densitometry analysis was carried out by Image Lab (right). Data are presented as mean ± SEM. Statistical analyses were conducted using one-way ANOVA followed by Dunnett’s multiple comparisons test. (D) Top pathways from LymphoChip upregulated in E788* cells compared to WT cells in the L-428 model. (E) Heatmap showing transcript levels of genes in the L-428 model. Genes with consistent expression changes (absolute fold change ≥ 1.4) across all three experimental models (L-428, U-HO1 + IL-3, U-HO1 + IL-5) are shown. (F) TARC and IL-13 concentrations in supernatant of L-428 model at baseline. Data are presented as mean ± SEM. Statistical analyses were conducted using one-way ANOVA followed by Dunnett’s multiple comparisons test (TARC), and a negative binomial regression model to account for overdispersion in the data (IL-13). (G) TARC and IL-13 concentrations in supernatant of L-428 (left) model treated with pacritinib (0.5 μM) for 48 hours, and U-HO1 (right) model in the presence of IL-3 (1 ng/mL) or IL-5 (1 ng/mL) treated with or without pacritinib (0.5 μM) for 48 hours. Data are presented as mean ± SEM. Pre- and post-treatment comparisons were conducted using an unpaired, two-sided t -test for each cell type. (H) CCR4+CD4+ T cell migration towards L-428 CSF2RB WT or E788* supernatant in a transwell migration assay, showing the percentage of migrated cells relative to the input control. A paired, two-sided t -test was used to compare the two conditions. Data are presented as mean ± SEM (n=4). (I) Spleen tissues from humanized mouse model, sacrificed at 12 weeks after CB injection, were stained with hematoxylin and eosin (H&E), CD30, CD4, PAX5, and FOXP3. The image is presented at a magnification of 20X. (J) Percentage of CD4+CD25+FOXP3+ Tregs identified in spleen of humanized CNW mice engrafted with L-428 CSF2RB WT or E788* cells by FCM. An unpaired, two-sided t -test was used to compare the two conditions, and data are shown as the mean ± SEM (n=6 for WT and n=5 for E788*). (K) Bar graph depicts serum TARC concentration from CNW mice engrafted L-428 WT (n=6) and E788* (n=5) cells, sacrificed at 12 weeks after CB injection. An unpaired, two-sided t -test was used to compare the two conditions. The data are shown as mean ± SEM.
    Figure Legend Snippet: (A) Proportion of mutation types across recurrently mutated genes. (B) Lollipop diagram depicting the distribution of CSF2RB mutations in our in-house cohort. (C) WB analysis of CSF2RB expression and phosphorylation status of STAT5 in the L-428 model. Representative images are shown (left). Densitometry analysis was carried out by Image Lab (right). Data are presented as mean ± SEM. Statistical analyses were conducted using one-way ANOVA followed by Dunnett’s multiple comparisons test. (D) Top pathways from LymphoChip upregulated in E788* cells compared to WT cells in the L-428 model. (E) Heatmap showing transcript levels of genes in the L-428 model. Genes with consistent expression changes (absolute fold change ≥ 1.4) across all three experimental models (L-428, U-HO1 + IL-3, U-HO1 + IL-5) are shown. (F) TARC and IL-13 concentrations in supernatant of L-428 model at baseline. Data are presented as mean ± SEM. Statistical analyses were conducted using one-way ANOVA followed by Dunnett’s multiple comparisons test (TARC), and a negative binomial regression model to account for overdispersion in the data (IL-13). (G) TARC and IL-13 concentrations in supernatant of L-428 (left) model treated with pacritinib (0.5 μM) for 48 hours, and U-HO1 (right) model in the presence of IL-3 (1 ng/mL) or IL-5 (1 ng/mL) treated with or without pacritinib (0.5 μM) for 48 hours. Data are presented as mean ± SEM. Pre- and post-treatment comparisons were conducted using an unpaired, two-sided t -test for each cell type. (H) CCR4+CD4+ T cell migration towards L-428 CSF2RB WT or E788* supernatant in a transwell migration assay, showing the percentage of migrated cells relative to the input control. A paired, two-sided t -test was used to compare the two conditions. Data are presented as mean ± SEM (n=4). (I) Spleen tissues from humanized mouse model, sacrificed at 12 weeks after CB injection, were stained with hematoxylin and eosin (H&E), CD30, CD4, PAX5, and FOXP3. The image is presented at a magnification of 20X. (J) Percentage of CD4+CD25+FOXP3+ Tregs identified in spleen of humanized CNW mice engrafted with L-428 CSF2RB WT or E788* cells by FCM. An unpaired, two-sided t -test was used to compare the two conditions, and data are shown as the mean ± SEM (n=6 for WT and n=5 for E788*). (K) Bar graph depicts serum TARC concentration from CNW mice engrafted L-428 WT (n=6) and E788* (n=5) cells, sacrificed at 12 weeks after CB injection. An unpaired, two-sided t -test was used to compare the two conditions. The data are shown as mean ± SEM.

    Techniques Used: Mutagenesis, Expressing, Migration, Transwell Migration Assay, Control, Injection, Staining, Concentration Assay



    Similar Products

    csf2rb  (Santa Cruz Biotechnology)
    93
    Santa Cruz Biotechnology csf2rb
    (A) Proportion of mutation types across recurrently mutated genes. (B) Lollipop diagram depicting the distribution of <t>CSF2RB</t> mutations in our in-house cohort. (C) WB analysis of CSF2RB expression and phosphorylation status of STAT5 in the L-428 model. Representative images are shown (left). Densitometry analysis was carried out by Image Lab (right). Data are presented as mean ± SEM. Statistical analyses were conducted using one-way ANOVA followed by Dunnett’s multiple comparisons test. (D) Top pathways from LymphoChip upregulated in E788* cells compared to WT cells in the L-428 model. (E) Heatmap showing transcript levels of genes in the L-428 model. Genes with consistent expression changes (absolute fold change ≥ 1.4) across all three experimental models (L-428, U-HO1 + IL-3, U-HO1 + IL-5) are shown. (F) TARC and IL-13 concentrations in supernatant of L-428 model at baseline. Data are presented as mean ± SEM. Statistical analyses were conducted using one-way ANOVA followed by Dunnett’s multiple comparisons test (TARC), and a negative binomial regression model to account for overdispersion in the data (IL-13). (G) TARC and IL-13 concentrations in supernatant of L-428 (left) model treated with pacritinib (0.5 μM) for 48 hours, and U-HO1 (right) model in the presence of IL-3 (1 ng/mL) or IL-5 (1 ng/mL) treated with or without pacritinib (0.5 μM) for 48 hours. Data are presented as mean ± SEM. Pre- and post-treatment comparisons were conducted using an unpaired, two-sided t -test for each cell type. (H) CCR4+CD4+ T cell migration towards L-428 CSF2RB WT or E788* supernatant in a transwell migration assay, showing the percentage of migrated cells relative to the input control. A paired, two-sided t -test was used to compare the two conditions. Data are presented as mean ± SEM (n=4). (I) Spleen tissues from humanized mouse model, sacrificed at 12 weeks after CB injection, were stained with hematoxylin and eosin (H&E), CD30, CD4, PAX5, and FOXP3. The image is presented at a magnification of 20X. (J) Percentage of CD4+CD25+FOXP3+ Tregs identified in spleen of humanized CNW mice engrafted with L-428 CSF2RB WT or E788* cells by FCM. An unpaired, two-sided t -test was used to compare the two conditions, and data are shown as the mean ± SEM (n=6 for WT and n=5 for E788*). (K) Bar graph depicts serum TARC concentration from CNW mice engrafted L-428 WT (n=6) and E788* (n=5) cells, sacrificed at 12 weeks after CB injection. An unpaired, two-sided t -test was used to compare the two conditions. The data are shown as mean ± SEM.
    Csf2rb, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/csf2rb/product/Santa Cruz Biotechnology
    Average 93 stars, based on 1 article reviews
    csf2rb - by Bioz Stars, 2026-03
    93/100 stars
    		  Buy from Supplier
    βcr  (Santa Cruz Biotechnology)
    93
    Santa Cruz Biotechnology βcr
    (A) Proportion of mutation types across recurrently mutated genes. (B) Lollipop diagram depicting the distribution of <t>CSF2RB</t> mutations in our in-house cohort. (C) WB analysis of CSF2RB expression and phosphorylation status of STAT5 in the L-428 model. Representative images are shown (left). Densitometry analysis was carried out by Image Lab (right). Data are presented as mean ± SEM. Statistical analyses were conducted using one-way ANOVA followed by Dunnett’s multiple comparisons test. (D) Top pathways from LymphoChip upregulated in E788* cells compared to WT cells in the L-428 model. (E) Heatmap showing transcript levels of genes in the L-428 model. Genes with consistent expression changes (absolute fold change ≥ 1.4) across all three experimental models (L-428, U-HO1 + IL-3, U-HO1 + IL-5) are shown. (F) TARC and IL-13 concentrations in supernatant of L-428 model at baseline. Data are presented as mean ± SEM. Statistical analyses were conducted using one-way ANOVA followed by Dunnett’s multiple comparisons test (TARC), and a negative binomial regression model to account for overdispersion in the data (IL-13). (G) TARC and IL-13 concentrations in supernatant of L-428 (left) model treated with pacritinib (0.5 μM) for 48 hours, and U-HO1 (right) model in the presence of IL-3 (1 ng/mL) or IL-5 (1 ng/mL) treated with or without pacritinib (0.5 μM) for 48 hours. Data are presented as mean ± SEM. Pre- and post-treatment comparisons were conducted using an unpaired, two-sided t -test for each cell type. (H) CCR4+CD4+ T cell migration towards L-428 CSF2RB WT or E788* supernatant in a transwell migration assay, showing the percentage of migrated cells relative to the input control. A paired, two-sided t -test was used to compare the two conditions. Data are presented as mean ± SEM (n=4). (I) Spleen tissues from humanized mouse model, sacrificed at 12 weeks after CB injection, were stained with hematoxylin and eosin (H&E), CD30, CD4, PAX5, and FOXP3. The image is presented at a magnification of 20X. (J) Percentage of CD4+CD25+FOXP3+ Tregs identified in spleen of humanized CNW mice engrafted with L-428 CSF2RB WT or E788* cells by FCM. An unpaired, two-sided t -test was used to compare the two conditions, and data are shown as the mean ± SEM (n=6 for WT and n=5 for E788*). (K) Bar graph depicts serum TARC concentration from CNW mice engrafted L-428 WT (n=6) and E788* (n=5) cells, sacrificed at 12 weeks after CB injection. An unpaired, two-sided t -test was used to compare the two conditions. The data are shown as mean ± SEM.
    βcr, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/βcr/product/Santa Cruz Biotechnology
    Average 93 stars, based on 1 article reviews
    βcr - by Bioz Stars, 2026-03
    93/100 stars
    		  Buy from Supplier
    antibodies against epor  (Santa Cruz Biotechnology)
    93
    Santa Cruz Biotechnology antibodies against epor
    (A) Proportion of mutation types across recurrently mutated genes. (B) Lollipop diagram depicting the distribution of <t>CSF2RB</t> mutations in our in-house cohort. (C) WB analysis of CSF2RB expression and phosphorylation status of STAT5 in the L-428 model. Representative images are shown (left). Densitometry analysis was carried out by Image Lab (right). Data are presented as mean ± SEM. Statistical analyses were conducted using one-way ANOVA followed by Dunnett’s multiple comparisons test. (D) Top pathways from LymphoChip upregulated in E788* cells compared to WT cells in the L-428 model. (E) Heatmap showing transcript levels of genes in the L-428 model. Genes with consistent expression changes (absolute fold change ≥ 1.4) across all three experimental models (L-428, U-HO1 + IL-3, U-HO1 + IL-5) are shown. (F) TARC and IL-13 concentrations in supernatant of L-428 model at baseline. Data are presented as mean ± SEM. Statistical analyses were conducted using one-way ANOVA followed by Dunnett’s multiple comparisons test (TARC), and a negative binomial regression model to account for overdispersion in the data (IL-13). (G) TARC and IL-13 concentrations in supernatant of L-428 (left) model treated with pacritinib (0.5 μM) for 48 hours, and U-HO1 (right) model in the presence of IL-3 (1 ng/mL) or IL-5 (1 ng/mL) treated with or without pacritinib (0.5 μM) for 48 hours. Data are presented as mean ± SEM. Pre- and post-treatment comparisons were conducted using an unpaired, two-sided t -test for each cell type. (H) CCR4+CD4+ T cell migration towards L-428 CSF2RB WT or E788* supernatant in a transwell migration assay, showing the percentage of migrated cells relative to the input control. A paired, two-sided t -test was used to compare the two conditions. Data are presented as mean ± SEM (n=4). (I) Spleen tissues from humanized mouse model, sacrificed at 12 weeks after CB injection, were stained with hematoxylin and eosin (H&E), CD30, CD4, PAX5, and FOXP3. The image is presented at a magnification of 20X. (J) Percentage of CD4+CD25+FOXP3+ Tregs identified in spleen of humanized CNW mice engrafted with L-428 CSF2RB WT or E788* cells by FCM. An unpaired, two-sided t -test was used to compare the two conditions, and data are shown as the mean ± SEM (n=6 for WT and n=5 for E788*). (K) Bar graph depicts serum TARC concentration from CNW mice engrafted L-428 WT (n=6) and E788* (n=5) cells, sacrificed at 12 weeks after CB injection. An unpaired, two-sided t -test was used to compare the two conditions. The data are shown as mean ± SEM.
    Antibodies Against Epor, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/antibodies against epor/product/Santa Cruz Biotechnology
    Average 93 stars, based on 1 article reviews
    antibodies against epor - by Bioz Stars, 2026-03
    93/100 stars
    		  Buy from Supplier
    anti βcr  (Santa Cruz Biotechnology)
    93
    Santa Cruz Biotechnology anti βcr
    (A) Proportion of mutation types across recurrently mutated genes. (B) Lollipop diagram depicting the distribution of <t>CSF2RB</t> mutations in our in-house cohort. (C) WB analysis of CSF2RB expression and phosphorylation status of STAT5 in the L-428 model. Representative images are shown (left). Densitometry analysis was carried out by Image Lab (right). Data are presented as mean ± SEM. Statistical analyses were conducted using one-way ANOVA followed by Dunnett’s multiple comparisons test. (D) Top pathways from LymphoChip upregulated in E788* cells compared to WT cells in the L-428 model. (E) Heatmap showing transcript levels of genes in the L-428 model. Genes with consistent expression changes (absolute fold change ≥ 1.4) across all three experimental models (L-428, U-HO1 + IL-3, U-HO1 + IL-5) are shown. (F) TARC and IL-13 concentrations in supernatant of L-428 model at baseline. Data are presented as mean ± SEM. Statistical analyses were conducted using one-way ANOVA followed by Dunnett’s multiple comparisons test (TARC), and a negative binomial regression model to account for overdispersion in the data (IL-13). (G) TARC and IL-13 concentrations in supernatant of L-428 (left) model treated with pacritinib (0.5 μM) for 48 hours, and U-HO1 (right) model in the presence of IL-3 (1 ng/mL) or IL-5 (1 ng/mL) treated with or without pacritinib (0.5 μM) for 48 hours. Data are presented as mean ± SEM. Pre- and post-treatment comparisons were conducted using an unpaired, two-sided t -test for each cell type. (H) CCR4+CD4+ T cell migration towards L-428 CSF2RB WT or E788* supernatant in a transwell migration assay, showing the percentage of migrated cells relative to the input control. A paired, two-sided t -test was used to compare the two conditions. Data are presented as mean ± SEM (n=4). (I) Spleen tissues from humanized mouse model, sacrificed at 12 weeks after CB injection, were stained with hematoxylin and eosin (H&E), CD30, CD4, PAX5, and FOXP3. The image is presented at a magnification of 20X. (J) Percentage of CD4+CD25+FOXP3+ Tregs identified in spleen of humanized CNW mice engrafted with L-428 CSF2RB WT or E788* cells by FCM. An unpaired, two-sided t -test was used to compare the two conditions, and data are shown as the mean ± SEM (n=6 for WT and n=5 for E788*). (K) Bar graph depicts serum TARC concentration from CNW mice engrafted L-428 WT (n=6) and E788* (n=5) cells, sacrificed at 12 weeks after CB injection. An unpaired, two-sided t -test was used to compare the two conditions. The data are shown as mean ± SEM.
    Anti βcr, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti βcr/product/Santa Cruz Biotechnology
    Average 93 stars, based on 1 article reviews
    anti βcr - by Bioz Stars, 2026-03
    93/100 stars
    		  Buy from Supplier
    pdgfr α  (Santa Cruz Biotechnology)
    93
    Santa Cruz Biotechnology pdgfr α
    (A) Proportion of mutation types across recurrently mutated genes. (B) Lollipop diagram depicting the distribution of <t>CSF2RB</t> mutations in our in-house cohort. (C) WB analysis of CSF2RB expression and phosphorylation status of STAT5 in the L-428 model. Representative images are shown (left). Densitometry analysis was carried out by Image Lab (right). Data are presented as mean ± SEM. Statistical analyses were conducted using one-way ANOVA followed by Dunnett’s multiple comparisons test. (D) Top pathways from LymphoChip upregulated in E788* cells compared to WT cells in the L-428 model. (E) Heatmap showing transcript levels of genes in the L-428 model. Genes with consistent expression changes (absolute fold change ≥ 1.4) across all three experimental models (L-428, U-HO1 + IL-3, U-HO1 + IL-5) are shown. (F) TARC and IL-13 concentrations in supernatant of L-428 model at baseline. Data are presented as mean ± SEM. Statistical analyses were conducted using one-way ANOVA followed by Dunnett’s multiple comparisons test (TARC), and a negative binomial regression model to account for overdispersion in the data (IL-13). (G) TARC and IL-13 concentrations in supernatant of L-428 (left) model treated with pacritinib (0.5 μM) for 48 hours, and U-HO1 (right) model in the presence of IL-3 (1 ng/mL) or IL-5 (1 ng/mL) treated with or without pacritinib (0.5 μM) for 48 hours. Data are presented as mean ± SEM. Pre- and post-treatment comparisons were conducted using an unpaired, two-sided t -test for each cell type. (H) CCR4+CD4+ T cell migration towards L-428 CSF2RB WT or E788* supernatant in a transwell migration assay, showing the percentage of migrated cells relative to the input control. A paired, two-sided t -test was used to compare the two conditions. Data are presented as mean ± SEM (n=4). (I) Spleen tissues from humanized mouse model, sacrificed at 12 weeks after CB injection, were stained with hematoxylin and eosin (H&E), CD30, CD4, PAX5, and FOXP3. The image is presented at a magnification of 20X. (J) Percentage of CD4+CD25+FOXP3+ Tregs identified in spleen of humanized CNW mice engrafted with L-428 CSF2RB WT or E788* cells by FCM. An unpaired, two-sided t -test was used to compare the two conditions, and data are shown as the mean ± SEM (n=6 for WT and n=5 for E788*). (K) Bar graph depicts serum TARC concentration from CNW mice engrafted L-428 WT (n=6) and E788* (n=5) cells, sacrificed at 12 weeks after CB injection. An unpaired, two-sided t -test was used to compare the two conditions. The data are shown as mean ± SEM.
    Pdgfr α, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pdgfr α/product/Santa Cruz Biotechnology
    Average 93 stars, based on 1 article reviews
    pdgfr α - by Bioz Stars, 2026-03
    93/100 stars
    		  Buy from Supplier
    p tyr py99 sc 7020 af790  (Santa Cruz Biotechnology)
    93
    Santa Cruz Biotechnology p tyr py99 sc 7020 af790
    (A) Proportion of mutation types across recurrently mutated genes. (B) Lollipop diagram depicting the distribution of <t>CSF2RB</t> mutations in our in-house cohort. (C) WB analysis of CSF2RB expression and phosphorylation status of STAT5 in the L-428 model. Representative images are shown (left). Densitometry analysis was carried out by Image Lab (right). Data are presented as mean ± SEM. Statistical analyses were conducted using one-way ANOVA followed by Dunnett’s multiple comparisons test. (D) Top pathways from LymphoChip upregulated in E788* cells compared to WT cells in the L-428 model. (E) Heatmap showing transcript levels of genes in the L-428 model. Genes with consistent expression changes (absolute fold change ≥ 1.4) across all three experimental models (L-428, U-HO1 + IL-3, U-HO1 + IL-5) are shown. (F) TARC and IL-13 concentrations in supernatant of L-428 model at baseline. Data are presented as mean ± SEM. Statistical analyses were conducted using one-way ANOVA followed by Dunnett’s multiple comparisons test (TARC), and a negative binomial regression model to account for overdispersion in the data (IL-13). (G) TARC and IL-13 concentrations in supernatant of L-428 (left) model treated with pacritinib (0.5 μM) for 48 hours, and U-HO1 (right) model in the presence of IL-3 (1 ng/mL) or IL-5 (1 ng/mL) treated with or without pacritinib (0.5 μM) for 48 hours. Data are presented as mean ± SEM. Pre- and post-treatment comparisons were conducted using an unpaired, two-sided t -test for each cell type. (H) CCR4+CD4+ T cell migration towards L-428 CSF2RB WT or E788* supernatant in a transwell migration assay, showing the percentage of migrated cells relative to the input control. A paired, two-sided t -test was used to compare the two conditions. Data are presented as mean ± SEM (n=4). (I) Spleen tissues from humanized mouse model, sacrificed at 12 weeks after CB injection, were stained with hematoxylin and eosin (H&E), CD30, CD4, PAX5, and FOXP3. The image is presented at a magnification of 20X. (J) Percentage of CD4+CD25+FOXP3+ Tregs identified in spleen of humanized CNW mice engrafted with L-428 CSF2RB WT or E788* cells by FCM. An unpaired, two-sided t -test was used to compare the two conditions, and data are shown as the mean ± SEM (n=6 for WT and n=5 for E788*). (K) Bar graph depicts serum TARC concentration from CNW mice engrafted L-428 WT (n=6) and E788* (n=5) cells, sacrificed at 12 weeks after CB injection. An unpaired, two-sided t -test was used to compare the two conditions. The data are shown as mean ± SEM.
    P Tyr Py99 Sc 7020 Af790, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/p tyr py99 sc 7020 af790/product/Santa Cruz Biotechnology
    Average 93 stars, based on 1 article reviews
    p tyr py99 sc 7020 af790 - by Bioz Stars, 2026-03
    93/100 stars
    		  Buy from Supplier
    mouse monoclonal antibodies against il  (Santa Cruz Biotechnology)
    93
    Santa Cruz Biotechnology mouse monoclonal antibodies against il
    (A) Proportion of mutation types across recurrently mutated genes. (B) Lollipop diagram depicting the distribution of <t>CSF2RB</t> mutations in our in-house cohort. (C) WB analysis of CSF2RB expression and phosphorylation status of STAT5 in the L-428 model. Representative images are shown (left). Densitometry analysis was carried out by Image Lab (right). Data are presented as mean ± SEM. Statistical analyses were conducted using one-way ANOVA followed by Dunnett’s multiple comparisons test. (D) Top pathways from LymphoChip upregulated in E788* cells compared to WT cells in the L-428 model. (E) Heatmap showing transcript levels of genes in the L-428 model. Genes with consistent expression changes (absolute fold change ≥ 1.4) across all three experimental models (L-428, U-HO1 + IL-3, U-HO1 + IL-5) are shown. (F) TARC and IL-13 concentrations in supernatant of L-428 model at baseline. Data are presented as mean ± SEM. Statistical analyses were conducted using one-way ANOVA followed by Dunnett’s multiple comparisons test (TARC), and a negative binomial regression model to account for overdispersion in the data (IL-13). (G) TARC and IL-13 concentrations in supernatant of L-428 (left) model treated with pacritinib (0.5 μM) for 48 hours, and U-HO1 (right) model in the presence of IL-3 (1 ng/mL) or IL-5 (1 ng/mL) treated with or without pacritinib (0.5 μM) for 48 hours. Data are presented as mean ± SEM. Pre- and post-treatment comparisons were conducted using an unpaired, two-sided t -test for each cell type. (H) CCR4+CD4+ T cell migration towards L-428 CSF2RB WT or E788* supernatant in a transwell migration assay, showing the percentage of migrated cells relative to the input control. A paired, two-sided t -test was used to compare the two conditions. Data are presented as mean ± SEM (n=4). (I) Spleen tissues from humanized mouse model, sacrificed at 12 weeks after CB injection, were stained with hematoxylin and eosin (H&E), CD30, CD4, PAX5, and FOXP3. The image is presented at a magnification of 20X. (J) Percentage of CD4+CD25+FOXP3+ Tregs identified in spleen of humanized CNW mice engrafted with L-428 CSF2RB WT or E788* cells by FCM. An unpaired, two-sided t -test was used to compare the two conditions, and data are shown as the mean ± SEM (n=6 for WT and n=5 for E788*). (K) Bar graph depicts serum TARC concentration from CNW mice engrafted L-428 WT (n=6) and E788* (n=5) cells, sacrificed at 12 weeks after CB injection. An unpaired, two-sided t -test was used to compare the two conditions. The data are shown as mean ± SEM.
    Mouse Monoclonal Antibodies Against Il, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse monoclonal antibodies against il/product/Santa Cruz Biotechnology
    Average 93 stars, based on 1 article reviews
    mouse monoclonal antibodies against il - by Bioz Stars, 2026-03
    93/100 stars
    		  Buy from Supplier
    anti csf2rb antibody  (Santa Cruz Biotechnology)
    93
    Santa Cruz Biotechnology anti csf2rb antibody
    (A) Proportion of mutation types across recurrently mutated genes. (B) Lollipop diagram depicting the distribution of <t>CSF2RB</t> mutations in our in-house cohort. (C) WB analysis of CSF2RB expression and phosphorylation status of STAT5 in the L-428 model. Representative images are shown (left). Densitometry analysis was carried out by Image Lab (right). Data are presented as mean ± SEM. Statistical analyses were conducted using one-way ANOVA followed by Dunnett’s multiple comparisons test. (D) Top pathways from LymphoChip upregulated in E788* cells compared to WT cells in the L-428 model. (E) Heatmap showing transcript levels of genes in the L-428 model. Genes with consistent expression changes (absolute fold change ≥ 1.4) across all three experimental models (L-428, U-HO1 + IL-3, U-HO1 + IL-5) are shown. (F) TARC and IL-13 concentrations in supernatant of L-428 model at baseline. Data are presented as mean ± SEM. Statistical analyses were conducted using one-way ANOVA followed by Dunnett’s multiple comparisons test (TARC), and a negative binomial regression model to account for overdispersion in the data (IL-13). (G) TARC and IL-13 concentrations in supernatant of L-428 (left) model treated with pacritinib (0.5 μM) for 48 hours, and U-HO1 (right) model in the presence of IL-3 (1 ng/mL) or IL-5 (1 ng/mL) treated with or without pacritinib (0.5 μM) for 48 hours. Data are presented as mean ± SEM. Pre- and post-treatment comparisons were conducted using an unpaired, two-sided t -test for each cell type. (H) CCR4+CD4+ T cell migration towards L-428 CSF2RB WT or E788* supernatant in a transwell migration assay, showing the percentage of migrated cells relative to the input control. A paired, two-sided t -test was used to compare the two conditions. Data are presented as mean ± SEM (n=4). (I) Spleen tissues from humanized mouse model, sacrificed at 12 weeks after CB injection, were stained with hematoxylin and eosin (H&E), CD30, CD4, PAX5, and FOXP3. The image is presented at a magnification of 20X. (J) Percentage of CD4+CD25+FOXP3+ Tregs identified in spleen of humanized CNW mice engrafted with L-428 CSF2RB WT or E788* cells by FCM. An unpaired, two-sided t -test was used to compare the two conditions, and data are shown as the mean ± SEM (n=6 for WT and n=5 for E788*). (K) Bar graph depicts serum TARC concentration from CNW mice engrafted L-428 WT (n=6) and E788* (n=5) cells, sacrificed at 12 weeks after CB injection. An unpaired, two-sided t -test was used to compare the two conditions. The data are shown as mean ± SEM.
    Anti Csf2rb Antibody, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti csf2rb antibody/product/Santa Cruz Biotechnology
    Average 93 stars, based on 1 article reviews
    anti csf2rb antibody - by Bioz Stars, 2026-03
    93/100 stars
    		  Buy from Supplier
    sc 398246  (Santa Cruz Biotechnology)
    93
    Santa Cruz Biotechnology sc 398246
    (A) Proportion of mutation types across recurrently mutated genes. (B) Lollipop diagram depicting the distribution of <t>CSF2RB</t> mutations in our in-house cohort. (C) WB analysis of CSF2RB expression and phosphorylation status of STAT5 in the L-428 model. Representative images are shown (left). Densitometry analysis was carried out by Image Lab (right). Data are presented as mean ± SEM. Statistical analyses were conducted using one-way ANOVA followed by Dunnett’s multiple comparisons test. (D) Top pathways from LymphoChip upregulated in E788* cells compared to WT cells in the L-428 model. (E) Heatmap showing transcript levels of genes in the L-428 model. Genes with consistent expression changes (absolute fold change ≥ 1.4) across all three experimental models (L-428, U-HO1 + IL-3, U-HO1 + IL-5) are shown. (F) TARC and IL-13 concentrations in supernatant of L-428 model at baseline. Data are presented as mean ± SEM. Statistical analyses were conducted using one-way ANOVA followed by Dunnett’s multiple comparisons test (TARC), and a negative binomial regression model to account for overdispersion in the data (IL-13). (G) TARC and IL-13 concentrations in supernatant of L-428 (left) model treated with pacritinib (0.5 μM) for 48 hours, and U-HO1 (right) model in the presence of IL-3 (1 ng/mL) or IL-5 (1 ng/mL) treated with or without pacritinib (0.5 μM) for 48 hours. Data are presented as mean ± SEM. Pre- and post-treatment comparisons were conducted using an unpaired, two-sided t -test for each cell type. (H) CCR4+CD4+ T cell migration towards L-428 CSF2RB WT or E788* supernatant in a transwell migration assay, showing the percentage of migrated cells relative to the input control. A paired, two-sided t -test was used to compare the two conditions. Data are presented as mean ± SEM (n=4). (I) Spleen tissues from humanized mouse model, sacrificed at 12 weeks after CB injection, were stained with hematoxylin and eosin (H&E), CD30, CD4, PAX5, and FOXP3. The image is presented at a magnification of 20X. (J) Percentage of CD4+CD25+FOXP3+ Tregs identified in spleen of humanized CNW mice engrafted with L-428 CSF2RB WT or E788* cells by FCM. An unpaired, two-sided t -test was used to compare the two conditions, and data are shown as the mean ± SEM (n=6 for WT and n=5 for E788*). (K) Bar graph depicts serum TARC concentration from CNW mice engrafted L-428 WT (n=6) and E788* (n=5) cells, sacrificed at 12 weeks after CB injection. An unpaired, two-sided t -test was used to compare the two conditions. The data are shown as mean ± SEM.
    Sc 398246, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sc 398246/product/Santa Cruz Biotechnology
    Average 93 stars, based on 1 article reviews
    sc 398246 - by Bioz Stars, 2026-03
    93/100 stars
    		  Buy from Supplier
    mouse monoclonal crm1antibodies  (Santa Cruz Biotechnology)
    95
    Santa Cruz Biotechnology mouse monoclonal crm1antibodies
    (A) Proportion of mutation types across recurrently mutated genes. (B) Lollipop diagram depicting the distribution of <t>CSF2RB</t> mutations in our in-house cohort. (C) WB analysis of CSF2RB expression and phosphorylation status of STAT5 in the L-428 model. Representative images are shown (left). Densitometry analysis was carried out by Image Lab (right). Data are presented as mean ± SEM. Statistical analyses were conducted using one-way ANOVA followed by Dunnett’s multiple comparisons test. (D) Top pathways from LymphoChip upregulated in E788* cells compared to WT cells in the L-428 model. (E) Heatmap showing transcript levels of genes in the L-428 model. Genes with consistent expression changes (absolute fold change ≥ 1.4) across all three experimental models (L-428, U-HO1 + IL-3, U-HO1 + IL-5) are shown. (F) TARC and IL-13 concentrations in supernatant of L-428 model at baseline. Data are presented as mean ± SEM. Statistical analyses were conducted using one-way ANOVA followed by Dunnett’s multiple comparisons test (TARC), and a negative binomial regression model to account for overdispersion in the data (IL-13). (G) TARC and IL-13 concentrations in supernatant of L-428 (left) model treated with pacritinib (0.5 μM) for 48 hours, and U-HO1 (right) model in the presence of IL-3 (1 ng/mL) or IL-5 (1 ng/mL) treated with or without pacritinib (0.5 μM) for 48 hours. Data are presented as mean ± SEM. Pre- and post-treatment comparisons were conducted using an unpaired, two-sided t -test for each cell type. (H) CCR4+CD4+ T cell migration towards L-428 CSF2RB WT or E788* supernatant in a transwell migration assay, showing the percentage of migrated cells relative to the input control. A paired, two-sided t -test was used to compare the two conditions. Data are presented as mean ± SEM (n=4). (I) Spleen tissues from humanized mouse model, sacrificed at 12 weeks after CB injection, were stained with hematoxylin and eosin (H&E), CD30, CD4, PAX5, and FOXP3. The image is presented at a magnification of 20X. (J) Percentage of CD4+CD25+FOXP3+ Tregs identified in spleen of humanized CNW mice engrafted with L-428 CSF2RB WT or E788* cells by FCM. An unpaired, two-sided t -test was used to compare the two conditions, and data are shown as the mean ± SEM (n=6 for WT and n=5 for E788*). (K) Bar graph depicts serum TARC concentration from CNW mice engrafted L-428 WT (n=6) and E788* (n=5) cells, sacrificed at 12 weeks after CB injection. An unpaired, two-sided t -test was used to compare the two conditions. The data are shown as mean ± SEM.
    Mouse Monoclonal Crm1antibodies, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse monoclonal crm1antibodies/product/Santa Cruz Biotechnology
    Average 95 stars, based on 1 article reviews
    mouse monoclonal crm1antibodies - by Bioz Stars, 2026-03
    95/100 stars
    		  Buy from Supplier

    Image Search Results


    (A) Proportion of mutation types across recurrently mutated genes. (B) Lollipop diagram depicting the distribution of CSF2RB mutations in our in-house cohort. (C) WB analysis of CSF2RB expression and phosphorylation status of STAT5 in the L-428 model. Representative images are shown (left). Densitometry analysis was carried out by Image Lab (right). Data are presented as mean ± SEM. Statistical analyses were conducted using one-way ANOVA followed by Dunnett’s multiple comparisons test. (D) Top pathways from LymphoChip upregulated in E788* cells compared to WT cells in the L-428 model. (E) Heatmap showing transcript levels of genes in the L-428 model. Genes with consistent expression changes (absolute fold change ≥ 1.4) across all three experimental models (L-428, U-HO1 + IL-3, U-HO1 + IL-5) are shown. (F) TARC and IL-13 concentrations in supernatant of L-428 model at baseline. Data are presented as mean ± SEM. Statistical analyses were conducted using one-way ANOVA followed by Dunnett’s multiple comparisons test (TARC), and a negative binomial regression model to account for overdispersion in the data (IL-13). (G) TARC and IL-13 concentrations in supernatant of L-428 (left) model treated with pacritinib (0.5 μM) for 48 hours, and U-HO1 (right) model in the presence of IL-3 (1 ng/mL) or IL-5 (1 ng/mL) treated with or without pacritinib (0.5 μM) for 48 hours. Data are presented as mean ± SEM. Pre- and post-treatment comparisons were conducted using an unpaired, two-sided t -test for each cell type. (H) CCR4+CD4+ T cell migration towards L-428 CSF2RB WT or E788* supernatant in a transwell migration assay, showing the percentage of migrated cells relative to the input control. A paired, two-sided t -test was used to compare the two conditions. Data are presented as mean ± SEM (n=4). (I) Spleen tissues from humanized mouse model, sacrificed at 12 weeks after CB injection, were stained with hematoxylin and eosin (H&E), CD30, CD4, PAX5, and FOXP3. The image is presented at a magnification of 20X. (J) Percentage of CD4+CD25+FOXP3+ Tregs identified in spleen of humanized CNW mice engrafted with L-428 CSF2RB WT or E788* cells by FCM. An unpaired, two-sided t -test was used to compare the two conditions, and data are shown as the mean ± SEM (n=6 for WT and n=5 for E788*). (K) Bar graph depicts serum TARC concentration from CNW mice engrafted L-428 WT (n=6) and E788* (n=5) cells, sacrificed at 12 weeks after CB injection. An unpaired, two-sided t -test was used to compare the two conditions. The data are shown as mean ± SEM.

    Journal: bioRxiv

    Article Title: Multidimensional characterization of cellular ecosystems in Hodgkin lymphoma

    doi: 10.1101/2025.03.18.643177

    Figure Lengend Snippet: (A) Proportion of mutation types across recurrently mutated genes. (B) Lollipop diagram depicting the distribution of CSF2RB mutations in our in-house cohort. (C) WB analysis of CSF2RB expression and phosphorylation status of STAT5 in the L-428 model. Representative images are shown (left). Densitometry analysis was carried out by Image Lab (right). Data are presented as mean ± SEM. Statistical analyses were conducted using one-way ANOVA followed by Dunnett’s multiple comparisons test. (D) Top pathways from LymphoChip upregulated in E788* cells compared to WT cells in the L-428 model. (E) Heatmap showing transcript levels of genes in the L-428 model. Genes with consistent expression changes (absolute fold change ≥ 1.4) across all three experimental models (L-428, U-HO1 + IL-3, U-HO1 + IL-5) are shown. (F) TARC and IL-13 concentrations in supernatant of L-428 model at baseline. Data are presented as mean ± SEM. Statistical analyses were conducted using one-way ANOVA followed by Dunnett’s multiple comparisons test (TARC), and a negative binomial regression model to account for overdispersion in the data (IL-13). (G) TARC and IL-13 concentrations in supernatant of L-428 (left) model treated with pacritinib (0.5 μM) for 48 hours, and U-HO1 (right) model in the presence of IL-3 (1 ng/mL) or IL-5 (1 ng/mL) treated with or without pacritinib (0.5 μM) for 48 hours. Data are presented as mean ± SEM. Pre- and post-treatment comparisons were conducted using an unpaired, two-sided t -test for each cell type. (H) CCR4+CD4+ T cell migration towards L-428 CSF2RB WT or E788* supernatant in a transwell migration assay, showing the percentage of migrated cells relative to the input control. A paired, two-sided t -test was used to compare the two conditions. Data are presented as mean ± SEM (n=4). (I) Spleen tissues from humanized mouse model, sacrificed at 12 weeks after CB injection, were stained with hematoxylin and eosin (H&E), CD30, CD4, PAX5, and FOXP3. The image is presented at a magnification of 20X. (J) Percentage of CD4+CD25+FOXP3+ Tregs identified in spleen of humanized CNW mice engrafted with L-428 CSF2RB WT or E788* cells by FCM. An unpaired, two-sided t -test was used to compare the two conditions, and data are shown as the mean ± SEM (n=6 for WT and n=5 for E788*). (K) Bar graph depicts serum TARC concentration from CNW mice engrafted L-428 WT (n=6) and E788* (n=5) cells, sacrificed at 12 weeks after CB injection. An unpaired, two-sided t -test was used to compare the two conditions. The data are shown as mean ± SEM.

    Article Snippet: Immunoblotting was performed as previously described( Alig et al ., 2023 ) using the following primary antibodies: STAT1 Rabbit mAb (D1K9Y), STAT3 Mouse mAb (124H6), STAT6 Rabbit mAb (D3H4), AKT(pan) Rabbit mAb (C67E7), Phospho-STAT1 (Y701) Rabbit mAb (58D6), Phospho-STAT3 (Y705) Rabbit mAb (D3A7), Phospho-STAT5 (Y694) Rabbit mAb (C11C5), Phospho-STAT6 (Y641) Rabbit mAb (C11A12), Phospho-AKT (S473) Rabbit mAb (193H12), GAPDH Rabbit mAb (14C10) (all from Cell Signaling Technology, dilution 1:1000), STAT5 Rabbit polyclonalAb (C-17) (dilution 1:5000), CSF2RB (IL-3/IL-5/GM-CSFRβ Mouse mAb (A-3) (dilution 1:100) (Santa Cruz Biotechnology), followed by secondary staining using anti-Mouse (dilution 1:10000; Promega, catalog no. W4021) or Rabbit IgG (H+L) HRP conjugate (dilution 1:5000; Promega, catalog no. W4011), and detected using Amersham ECL Detection Reagents (Cytiva, catalog no. RPN3004).

    Techniques: Mutagenesis, Expressing, Migration, Transwell Migration Assay, Control, Injection, Staining, Concentration Assay